Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity - PubMed (original) (raw)
Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity
Jung-Kil Lee et al. J Neurosci. 2004.
Abstract
After ischemic stroke, partial recovery of function frequently occurs and may depend on the plasticity of axonal connections. Here, we examine whether blockade of the Nogo-NogoReceptor (NgR) pathway might enhance axonal sprouting and thereby recovery after focal brain infarction. Mutant mice lacking NgR or Nogo-AB recover complex motor function after stroke more completely than do control animals. After a stroke, greater numbers of axons emanating from the undamaged cortex cross the midline to innervate the contralateral red nucleus and the ipsilateral cervical spinal cord; this axonal plasticity is enhanced in ngr -/- or nogo-ab -/- mice. In rats with middle cerebral artery occlusion, both the recovery of motor skills and corticofugal axonal plasticity are promoted by intracerebroventricular administration of a function-blocking NgR fragment. Behavioral improvement occurs when therapy is initiated 1 week after arterial occlusion. Thus, delayed pharmacological blockade of the NgR promotes subacute stroke recovery by facilitating axonal plasticity.
Figures
Figure 1.
Behavioral recovery after stroke in ngr -/- mice. A, B, Cresyl violet-stained coronal brain sections 28 d after photothrombosis. There is no difference in total infarct volume between ngr +/- and ngr -/- mice. C, Staircase test of skilled forelimb reaching ability. The photothrombotic lesion reduces the number of pellets retrieved with the contralateral forepaw. Significantly greater recovery during the postoperative period is observed in the ngr -/- mice. **p < 0.01 (two-way parametric ANOVA). D, Rotarod performance at baseline is presented as the time spent on an accelerating rotarod at final pre-stroke training session. *Significantly different from ngr +/-; p < 0.05 (Student's t test). E, Rotoarod performance is expressed as a ratio to baseline (pre-lesion) performance at various times after stroke in mice of the indicated genotypes. Performance was significantly better in ngr -/- mice after stroke. *p < 0.05 (two-way parametric ANOVA). Data are mean ± SEM from different animals. n = 10 mice for ngr +/- and n = 11 mice for ngr -/- in _B_-E.
Figure 2.
Corticofugal axonal plasticity after stroke in ngr -/- mice. A, B, BDA-labeled axons traced from the uninjured cerebral cortex are illustrated in coronal sections at the level of the red nucleus (A) and transverse sections of cervical spinal cord (B) from different mice. Both ngr +/- and ngr -/- mice without stroke possess very few BDA-labeled fibers in the red nucleus contralateral to the tracer injection (arrow) or in the spinal gray matter ipsilateral to the injection (arrows). After stroke, the number of such fibers increases to a greater extent in the ngr -/- mice. Dorsal is up and the lesioned side is to the right in this and all micrographs. C, The total BDA-positive axon length per area of a coronal section centered on the red nucleus is plotted as a function of the side, genotype, and stroke. D, The total number of BDA-positive axons in the gray matter ipsilateral to the injection site per transverse section of the cervical spinal cord is plotted for the indicated conditions. Data are mean ± SEM from different animals. n = 10 mice for ngr +/- and n = 11 mice for ngr -/- in C, D. *p < 0.05; **p < 0.01 (Student's t test).
Figure 3.
Recovery from cortical photothrombosis in mice lacking Nogo-AB. A, B, Cresyl violet-stained coronal brain sections 28 d after photothrombosis. Total infarct volume in nogo-ab -/- mice is smaller than nogo-ab +/- mice, although the difference is not significant at the p < 0.05 level. C, D, Staircase test and rotarod test performance after stroke. Performance across the postoperative period is significantly improved in nogo-ab -/- mice relative to the nogo-ab +/- mice. ***p < 0.001 (two-way parametric ANOVA). Data are mean ± SEM from different animals. n = 10 mice for nogo-ab +/- and n = 9 nogo-ab -/- mice in _B_-D.
Figure 4.
Corticofugal axonal plasticity after stroke in mice lacking Nogo-AB. A, B, BDA-labeled axons traced from the uninjured cerebral cortex are illustrated at the level of the red nucleus (A) and cervical spinal cord (B) from different mice. In non-stroke mice there are few BDA-labeled fibers in the red nucleus contralateral to the tracer injection (arrow) or in the spinal gray matter ipsilateral to the injection (arrows), regardless of genotype. After stroke, the number of fibers sprouting into these areas increases to a higher level in the nogo-ab -/- mice. C, The total BDA-positive axon length per area of a coronal section centered on the red nucleus is plotted as a function of the side, genotype, and stroke. D, The total number of BDA-positive axons in the gray matter ipsilateral to the injection site per transverse section of the cervical spinal cord is plotted for the indicated conditions. Data are mean ± SEM from different animals. n = 10 mice for nogo-ab +/- and n = 9 nogo-ab -/- mice in C, D. *p < 0.05; **p < 0.01 (Student's t test).
Figure 5.
NgR(310)Ecto-Fc treatment of rats with MCAO stroke. A, Cresyl violet-stained sections of rat brain 77 d after MCAO and after intracerebroventricular treatment from day 7 to 63 with either IgG or NgR(310)Ecto-Fc. B, Stroke volume. There is no significant effect of NgR(310)Ecto-Fc on infarct volume. C, Staircase test. The number of pellets retrieved with the contralateral forepaw is significantly increased in the NgR(310)Ecto-Fc group compared with the control group. ***p < 0.001 (two-way parametric ANOVA). D, Rotarod test. Postoperative performance ratio to baseline was significantly better in rats treated with NgR(310)Ecto-Fc. **p < 0.01 (two-way parametric ANOVA). Data are mean ± SEM from different animals. n = 16 rats for IgG and n = 17 rats for NgR(310)Ecto-Fc in _B_-D.
Figure 6.
Corticofugal axonal plasticity after MCAO in rats treated with NgR(310)Ecto-Fc. A, B, BDA-labeled axons traced from the uninjured cerebral cortex are illustrated at the level of the red nucleus (A) and cervical spinal cord (B) from different rats. Control rats with no stroke and no treatment exhibit very few BDA-labeled fibers in the red nucleus contralateral to the tracer injection (arrow) or in the spinal gray matter ipsilateral to the injection (arrows). After stroke, many BDA-labeled fibers sprouting into the territory normally innervated by the infracted cortex are present. This is more prominent in rats treated with NgR(310)Ecto-Fc than in control IgG rats. C, The total BDA-positive axon length per area of a coronal section centered on the red nucleus is plotted as a function of the side, protein infusion, and stroke. D, The total number of BDA-positive axons in the gray matter ipsilateral to the injection site per transverse section of the cervical spinal cord is plotted for the indicated conditions. Data are mean ± SEM from different animals. n = 16 rats for IgG and n = 17 rats for NgR(310)Ecto-Fc in C, D. *p < 0.05; **p < 0.01 (Student's t test).
Similar articles
- Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury.
Li S, Liu BP, Budel S, Li M, Ji B, Walus L, Li W, Jirik A, Rabacchi S, Choi E, Worley D, Sah DW, Pepinsky B, Lee D, Relton J, Strittmatter SM. Li S, et al. J Neurosci. 2004 Nov 17;24(46):10511-20. doi: 10.1523/JNEUROSCI.2828-04.2004. J Neurosci. 2004. PMID: 15548666 Free PMC article. - Down-regulation of Nogo receptor promotes functional recovery by enhancing axonal connectivity after experimental stroke in rats.
Wang T, Wang J, Yin C, Liu R, Zhang JH, Qin X. Wang T, et al. Brain Res. 2010 Nov 11;1360:147-58. doi: 10.1016/j.brainres.2010.08.101. Epub 2010 Sep 7. Brain Res. 2010. PMID: 20828545 - Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat.
Cao Y, Shumsky JS, Sabol MA, Kushner RA, Strittmatter S, Hamers FP, Lee DH, Rabacchi SA, Murray M. Cao Y, et al. Neurorehabil Neural Repair. 2008 May-Jun;22(3):262-78. doi: 10.1177/1545968307308550. Epub 2007 Nov 30. Neurorehabil Neural Repair. 2008. PMID: 18056009 Free PMC article. - The Nogo receptor, its ligands and axonal regeneration in the spinal cord; a review.
Hunt D, Coffin RS, Anderson PN. Hunt D, et al. J Neurocytol. 2002 Feb;31(2):93-120. doi: 10.1023/a:1023941421781. J Neurocytol. 2002. PMID: 12815233 Review. - Nogo and Nogo receptor: relevance to schizophrenia?
Willi R, Schwab ME. Willi R, et al. Neurobiol Dis. 2013 Jun;54:150-7. doi: 10.1016/j.nbd.2013.01.011. Epub 2013 Jan 28. Neurobiol Dis. 2013. PMID: 23369871 Review.
Cited by
- Development of neural repair therapy for chronic spinal cord trauma: soluble Nogo receptor decoy from discovery to clinical trial.
Howard EM, Strittmatter SM. Howard EM, et al. Curr Opin Neurol. 2023 Dec 1;36(6):516-522. doi: 10.1097/WCO.0000000000001205. Epub 2023 Sep 19. Curr Opin Neurol. 2023. PMID: 37865850 Review. - Anti-Nogo-A Antibody Therapy Improves Functional Outcome Following Traumatic Brain Injury.
Powers BE, Ton ST, Farrer RG, Chaudhary S, Nockels RP, Kartje GL, Tsai SY. Powers BE, et al. Neurorehabil Neural Repair. 2023 Oct;37(10):682-693. doi: 10.1177/15459683231203194. Epub 2023 Oct 14. Neurorehabil Neural Repair. 2023. PMID: 37837331 Free PMC article. - Astroglial Hmgb1 regulates postnatal astrocyte morphogenesis and cerebrovascular maturation.
Freitas-Andrade M, Comin CH, Van Dyken P, Ouellette J, Raman-Nair J, Blakeley N, Liu QY, Leclerc S, Pan Y, Liu Z, Carrier M, Thakur K, Savard A, Rurak GM, Tremblay MÈ, Salmaso N, da F Costa L, Coppola G, Lacoste B. Freitas-Andrade M, et al. Nat Commun. 2023 Aug 16;14(1):4965. doi: 10.1038/s41467-023-40682-3. Nat Commun. 2023. PMID: 37587100 Free PMC article. - Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
Maynard G, Kannan R, Liu J, Wang W, Lam TKT, Wang X, Adamson C, Hackett C, Schwab JM, Liu C, Leslie DP, Chen D, Marino R, Zafonte R, Flanders A, Block G, Smith E, Strittmatter SM. Maynard G, et al. Lancet Neurol. 2023 Aug;22(8):672-684. doi: 10.1016/S1474-4422(23)00215-6. Lancet Neurol. 2023. PMID: 37479373 Free PMC article. Clinical Trial. - Microglial Nogo delays recovery following traumatic brain injury in mice.
Glotfelty EJ, Hsueh SC, Claybourne Q, Bedolla A, Kopp KO, Wallace T, Zheng B, Luo Y, Karlsson TE, McDevitt RA, Olson L, Greig NH. Glotfelty EJ, et al. Glia. 2023 Oct;71(10):2473-2494. doi: 10.1002/glia.24436. Epub 2023 Jul 4. Glia. 2023. PMID: 37401784 Free PMC article.
References
- Acevedo L, Yu J, Erdjument-Bromage H, Qing Miao R, Kim J-E, Fulton D, Tempst P, Strittmatter SM, Sessa WC (2004) A novel role for Nogo as a regulator of vascular remodeling. Nat Med 10: 382-388. - PubMed
- Baird AL, Meldrum A, Dunnett SB (2001) The staircase test of skilled reaching in mice. Brain Res Bull 54: 243-250. - PubMed
- Bartsch U, Bandtlow CE, Schnell L, Bartsch S, Spillmann AA, Rubin BP, Hillenbrand R, Montag D, Schwab ME, Schachner M (1995) Lack of evidence that myelin-associated glycoprotein is a major inhibitor of axonal regeneration in the CNS. Neuron 15: 1375-1381. - PubMed
- Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD (1996) Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 27: 1616-1622. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases